There is a growing drive, particularly in European circles, for the regulation — and perhaps prohibition — of germline engineering. This is becoming an increasingly heated area of discussion in the American health law community, with lines sharply drawn on both sides and litigation sure to follow.

Germline engineering is the attempt to transform the genetic code of living organisms–including humans–so as to change not only the particular individual organism, but its progeny as well, and it is viewed with fear by some critics.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]